SCHEMBL4192248

SCHEMBL4192248

O=c1c2c(Cc3ccc(C(F)(F)F)cc3)n[nH]c2c2cccnc2n1-c1cccc(OC(F)(F)F)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE1A P54750 1/20 0.42
PDE1B Q01064 1/20 0.42
PDE4B Q07343 1/20 0.38
PDE4D Q08499 1/20 0.38
PPARG P37231 1/20 0.36
EP300 Q09472 1/20 0.36
CREBBP Q92793 1/20 0.36
KAT2A Q92830 1/20 0.36
KAT2B Q92831 1/20 0.36
PARP1 P09874 1/20 0.35
KCNN4 O15554 2/20 0.35
IDO1 P14902 1/20 0.35
PTGDR2 Q9Y5Y4 1/20 0.34
CYP1A2 P05177 1/20 0.34
FFAR2 O15552 1/20 0.33
FLT1 P17948 1/20 0.33
KDR P35968 1/20 0.33
NR1H4 Q96RI1 1/20 0.33
TP53 P04637 1/20 0.33
POLB P06746 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4186970 0.94 PDE1A (0.44) PDE1APDE1BPDE4BPDE4DPARP1
SCHEMBL4183631 0.93 PDE1A (0.42) PDE1APDE1BPDE4BPDE4DPPARG
SCHEMBL4192370 0.93 PDE1A (0.42) PDE1APDE1BPDE4BPDE4DPPARG
SCHEMBL4180788 0.92 PARP1 (0.43) PDE1APDE1BPDE4BPDE4DPARP1
SCHEMBL4197165 0.92 PDE1A (0.51) PDE1APDE1BPDE4BPDE4DPPARG
SCHEMBL4187892 0.92 PDE1A (0.41) PDE1APDE1BPDE4BPDE4DPPARG
SCHEMBL4187720 0.91 PDE1A (0.45) PDE1APDE1BPDE4BPDE4DPPARG
SCHEMBL4185765 0.91 PDE1A (0.46) PDE1APDE1BPDE4BPDE4DPPARG
SCHEMBL4197168 0.88 PDE1A (0.50) PDE1APDE1BPDE4BPDE4DPPARG
SCHEMBL4182646 0.88 PDE1A (0.55) PDE1APDE1BPDE4BPDE4DEP300

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1925617-B1 HETEROCYCLIC COMPOUND, AND PRODUCTION PROCESS AND USE THEREOF ASKA PHARM CO LTD (JP) 2012-11-14 EP disclosed
US-8193356-B2 Heterocycle compound, and production process and application thereof ASKA PHARMACEUTICAL CO., LTD. (JP) 2012-06-05 US disclosed
US-20090131467-A1 Heterocycle Compound, and Production Process and Application Thereof ASKA PHARMACEUTICAL CO., LTD. (JP) 2009-05-21 US disclosed
EP-1925617-A1 HETEROCYCLIC COMPOUND, AND PRODUCTION PROCESS AND USE THEREOF ASKA Pharmaceutical Co., Ltd. (JP) 2008-05-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131467-A1 Heterocycle Compound, and Production Process and Application Thereof PDE3B, PDE4B, PDE7A PDE1A 26/4885PDE1B 21/4885PDE4B 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.